Barclays’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16K | Sell |
2,300
-16,231
| -88% | -$126K | ﹤0.01% | 4619 |
|
|
2025
Q4 | $131K | Buy |
18,531
+5,135
| +38% | +$39.6K | ﹤0.01% | 4499 |
|
|
2025
Q3 | $99.9K | Sell |
13,396
-10,608
| -44% | -$80.5K | ﹤0.01% | 4616 |
|
|
2025
Q2 | $176K | Buy |
24,004
+15,553
| +184% | +$136K | ﹤0.01% | 4355 |
|
|
2025
Q1 | $65.2K | Sell |
8,451
-2,092
| -20% | -$22.9K | ﹤0.01% | 4541 |
|
|
2024
Q4 | $128K | Buy |
10,543
+1,255
| +14% | +$16.1K | ﹤0.01% | 4521 |
|
|
2024
Q3 | $116K | Buy |
9,288
+6,855
| +282% | +$88.4K | ﹤0.01% | 4532 |
|
|
2024
Q2 | $29K | Buy |
+2,433
| New | +$33.4K | ﹤0.01% | 4368 |
|
|
2023
Q4 | – | Sell |
-4,014
| Closed | -$29K | – | 5268 |
|
|
2023
Q3 | $29K | Hold |
4,014
| – | – | ﹤0.01% | 4067 |
|
|
2023
Q2 | $21.2K | Hold |
4,014
| – | – | ﹤0.01% | 4124 |
|
|
2023
Q1 | $12.5K | Hold |
4,014
| – | – | ﹤0.01% | 4721 |
|
|
2022
Q4 | $15.9K | Hold |
4,014
| – | – | ﹤0.01% | 4853 |
|
|
2022
Q3 | $15K | Hold |
4,014
| – | – | ﹤0.01% | 4164 |
|
|
2022
Q2 | $54K | Hold |
4,014
| – | – | ﹤0.01% | 4009 |
|
|
2022
Q1 | $20K | Hold |
4,014
| – | – | ﹤0.01% | 4441 |
|
|
2021
Q4 | $28K | Sell |
4,014
-499
| -11% | -$8.53K | ﹤0.01% | 3917 |
|
|
2021
Q3 | $139K | Buy |
4,513
+29
| +0.6% | +$954 | ﹤0.01% | 3771 |
|
|
2021
Q2 | $145K | Sell |
4,484
-2,961
| -40% | -$102K | ﹤0.01% | 3689 |
|
|
2021
Q1 | $282K | Buy |
7,445
+3,569
| +92% | +$163K | ﹤0.01% | 3538 |
|
|
2020
Q4 | $183K | Sell |
3,876
-392
| -9% | -$17K | ﹤0.01% | 3808 |
|
|
2020
Q3 | $137K | Buy |
4,268
+2,055
| +93% | +$80.4K | ﹤0.01% | 4066 |
|
|
2020
Q2 | $97K | Buy |
2,213
+2,209
| +55,225% | +$104K | ﹤0.01% | 4537 |
|
|
2020
Q1 | $0 | Sell |
4
-108
| -96% | -$4.96K | ﹤0.01% | 6263 |
|
|
2019
Q4 | $6K | Sell |
112
-146
| -57% | -$6.12K | ﹤0.01% | 6157 |
|
|
2019
Q3 | $9K | Sell |
258
-4,427
| -94% | -$239K | ﹤0.01% | 6367 |
|
|
2019
Q2 | $259K | Buy |
4,685
+4,196
| +858% | +$262K | ﹤0.01% | 4880 |
|
|
2019
Q1 | $29K | Buy |
489
+439
| +878% | +$28.2K | ﹤0.01% | 6191 |
|
|
2018
Q4 | $3K | Sell |
50
-2,453
| -98% | -$181K | ﹤0.01% | 6609 |
|
|
2018
Q3 | $202K | Sell |
2,503
-2,683
| -52% | -$213K | ﹤0.01% | 4990 |
|
|
2018
Q2 | $454K | Buy |
5,186
+4,795
| +1,226% | +$841K | ﹤0.01% | 4037 |
|
|
2018
Q1 | $76K | Buy |
391
+347
| +789% | +$64.7K | ﹤0.01% | 5586 |
|
|
2017
Q4 | $5K | Buy |
44
+40
| +1,000% | +$2.04K | ﹤0.01% | 6665 |
|
|
2017
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 6919 |
|
|
2017
Q2 | $0 | Buy |
+4
| New | +$144 | ﹤0.01% | 6754 |
|
|
2014
Q4 | – | Sell |
-1
| Closed | -$2K | – | 7392 |
|
|
2014
Q3 | $2K | Sell |
1
-81
| -99% | -$200K | ﹤0.01% | 7397 |
|
|
2014
Q2 | $258K | Sell |
82
-22
| -21% | -$71.8K | ﹤0.01% | 4579 |
|
|
2014
Q1 | $328K | Buy |
104
+86
| +478% | +$318K | ﹤0.01% | 4311 |
|
|
2013
Q4 | $55K | Buy |
18
+11
| +157% | +$43.4K | ﹤0.01% | 6113 |
|
|
2013
Q3 | $28K | Sell |
7
-95
| -93% | -$382K | ﹤0.01% | 6371 |
|
|
2013
Q2 | $345K | Buy |
+102
| New | +$388K | ﹤0.01% | 4642 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
Barclays's GYRE Position: Q1 2026 in Review
Barclays reduced its Gyre Therapeutics (GYRE) stake by 88% in Q1 2026, selling an estimated $126K and leaving 2,300 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #4619.
Barclays first reported a position in GYRE in Q2 2013 and has held it in 40 quarters since. The position peaked at $454K in Q2 2018. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- Barclays held 2,300 shares of Gyre Therapeutics worth $16K as of Q1 2026.
- Barclays sold 16,231 Gyre Therapeutics shares in Q1 2026, an estimated $126K.
- Gyre Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4619 holding.
- Barclays first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 40 quarters since.
- Barclays's Gyre Therapeutics position peaked at $454K in Q2 2018.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.